Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer-Reference-Cited by-同舟云学术

Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer

Published:2021-12-01 Issue:12 Volume:7 Page:1782
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Melamed Alexander¹²³,Rauh-Hain J. Alejandro⁴,Gockley Allison A.¹²,Nitecki Roni⁴,Ramirez Pedro T.⁴,Hershman Dawn L.²³⁵⁶,Keating Nancy⁷⁸,Wright Jason D.¹²³

Affiliation:

1. Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York

2. NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York

3. Herbert Irving Comprehensive Cancer Center, New York, New York

4. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston

5. Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York

6. Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York

7. Department of Health Policy, Harvard Medical School, Boston, Massachusetts

8. Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2784404/jamaoncology_melamed_2021_oi_210063_1639155153.8981.pdf

Reference28 articles.

1. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.;Vergote;N Engl J Med,2010

2. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.;Kehoe;Lancet,2015

3. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.;Onda;Eur J Cancer,2020

4. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).;Fagotti;Int J Gynecol Cancer,2020

5. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline.;Wright;J Clin Oncol,2016

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strain and hyaluronic acid interact to regulate ovarian cancer cell proliferation, migration, and drug resistance;Mechanobiology in Medicine;2024-12

2. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

3. Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning;Gynecologic Oncology;2024-07

4. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group;Frontiers in Oncology;2024-06-04

5. Optimal outcomes in gynae‐oncology require honest and respectful conversations: Between ourselves and with our patients;BJOG: An International Journal of Obstetrics & Gynaecology;2024-05-27